Literature DB >> 19847200

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.

P Chevallier, T Prebet, A Pigneux, M Hunault, J Delaunay, F Perry, L Lode, S Richebourg, O Blanchet, N Vey, N Ifrah, N Milpied, D Blaise, J-L Harousseau, M Mohty.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19847200     DOI： 10.1038/leu.2009.214

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

Authors:  François Vergez; Alexa S Green; Jerome Tamburini; Jean-Emmanuel Sarry; Baptiste Gaillard; Pascale Cornillet-Lefebvre; Melanie Pannetier; Aymeric Neyret; Nicolas Chapuis; Norbert Ifrah; François Dreyfus; Stéphane Manenti; Cecile Demur; Eric Delabesse; Catherine Lacombe; Patrick Mayeux; Didier Bouscary; Christian Recher; Valerie Bardet
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.

Authors:  Roland B Walter; Bruno C Medeiros; Bayard L Powell; Charles A Schiffer; Frederick R Appelbaum; Elihu H Estey
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

3.  Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.

Authors:  Tim Pfeiffer; Michael Schleuning; Jiri Mayer; Karl-Heinz Haude; Johanna Tischer; Stefanie Buchholz; Donald Bunjes; Gesine Bug; Ernst Holler; Ralf G Meyer; Hildegard Greinix; Christof Scheid; Maximilian Christopeit; Susanne Schnittger; Jan Braess; Günter Schlimok; Karsten Spiekermann; Arnold Ganser; Hans-Jochem Kolb; Christoph Schmid
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 4.  High-dose cytarabine (HD araC) in the treatment of leukemias: a review.

Authors:  Nicholas D Reese; Gary J Schiller
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

Review 5.  Molecular markers in acute myeloid leukaemia.

Authors:  Andrea Kühnl; David Grimwade
Journal:  Int J Hematol       Date:  2012-07-13       Impact factor: 2.490

Review 6.  Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

7.  The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics.

Authors:  J How; J Sykes; M D Minden; V Gupta; K W L Yee; A D Schimmer; A C Schuh; S Kamel-Reid; J M Brandwein
Journal:  Blood Cancer J       Date:  2013-05-24       Impact factor: 11.037
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.